ArticleCurrent medical imaging2026
Association of Prostate Multiparametric MRI Parameters with Gleason Score: A Fusion Biopsy-Based Correlation
Article in Current medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diagnostic and Clinical Impact of Imaging Modality on PSA Density: TRUS Versus MRI in Gray-Zone Prostate Cancer.Current oncology (Toronto, Ont.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aimed to investigate the relationship between imaging parameters obtained from Multiparametric Magnetic Resonance İmaging (MPMRI) and Gleason Scores (GS) derived from targeted prostate biopsies performed using MRI/Ultrasound (US) fusion guidance. MATERIALS AND
methodsA total of 120 consecutive patients who underwent 1.5T MP-MRI followed by MRI/US fusion-guided prostate biopsy were included. In total, 202 MRI-identified targets were sampled. For each lesion, anatomical location, Prostate-Specific Antigen (PSA), prostate volume, Prostate Density (PD), apparent diffusion Coefficient (ADC) values, neurovascular bundle invasion, and PI-RADS v2.1 score were recorded. GS results were statistically compared with imaging and clinical parameters. Pearson’s correlation was calculated to investigate the associations, and the diagnostic ability of ADC values was evaluated by Receiver Operating Characteristic (ROC) analysis.
resultsOf the 202 targets, 138 (68.3%) were benign, 35 (17.3%) had GS 3+4 (low-grade), and 29 (14.4%) had GS ≥4+3 (high-grade) malignancy. ADC values were negatively correlated with age, PSA, PD, and PI-RADS score. Most lesions were located in the peripheral zone, particularly in the mid-gland and apical regions. Malignant lesions were frequently found in the peripheral zone and right mid-gland. ADC values showed strong diagnostic performance, with cut-offs of 0.78 ×10−3 mm2/s for low-grade (sensitivity: 79.69%, specificity: 86.21%) and 0.70 ×10−3mm2/s for highgrade malignancies (sensitivity: 92.03%, specificity: 92.49%). DISCUSSION: This echoes previous reports indicating that ADC value negatively correlated with GS, supporting the application of MP-MRI-derived parameters in the assessment of prostate cancer.
conclusionCorrelation of MP-MRI-derived imaging parameters with histopathology results allows meaningful exploitation in clinical decision-making in prostate cancer diagnosis. Both the PI-RADS score and the ADC value were validated as reliable predictors of tumor aggressiveness. Although MRI-targeted fusion biopsies have gained more and more popularity in clinical practice, based on our data, no conclusion can be drawn as to their effect in decreasing the number of unnecessary prostate biopsies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.